Stearyl amine tailored spanlastics embedded within tetronic® nanogel for boosting the repurposed anticancer potential of mebendazole: formulation, in vitro profiling, cytotoxicity assessment, and in vivo permeation analysis
DARU Journal of Pharmaceutical Sciences · 2025
DOI: 10.1007/s40199-025-00560-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, 2025. Verfasst von Mai El Halawany und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr El-Ainy Street 11562, Cairo, Egypt. Hauptthemen laut MEDLINE: Mebendazole, Antineoplastic Agents, Amines, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Mebendazole (MBZ) is an anthelmintic drug that was repurposed as an anti-cancer agent. OBJECTIVES: This study aimed at formulating MBZ into stearylamine tailored spanlastics dispersed in nanogel for enhancing MBZ anti-tumor efficacy against skin cancer. METHODS: MBZ spanlastics were prepared by thin film hydration using 21 × 31 factorial design. The formulation variables were the total amount (mg) of Span 60 and Tween 80 in the formulations and the ratio between Span 60 and Tween 80. RESULTS: Optimal spanlastics formulation was composed of 400 mg of Span 60 and Tween 80 in a ratio of 2:1 and showed EE% of 78 ± 2.9% and PS of 284.00 ± 35.36 nm. Stearylamine (20 mg) was added to the optimized formulation and showed acceptable positive charge (zeta potential = 47.53 ± 1.50 mV). It was dispersed in 30% Tetronic®1107 solution to form a nanogel. MBZ nanogel was assessed for their cytotoxic effect on cell proliferation against human malignant melanoma and epidermoid carcinoma cell lines and showed 38.70 ± 1.70% and 48.60 ± 0.50% (respectively) cell proliferation compared to the control group (100%). Finally, its permeation through Wistar rat skin was tested. CONCLUSION: SA-spanlastics nanogel holds potential as an effective nanocarrier for boosting MBZ anti-cancer efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr El-Ainy Street 11562, Cairo, Egypt.
- Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr El-Ainy Street 11562, Cairo, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Ahram Canadian University, 6Th October City 12573, Giza, Egypt.
- Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr El-Ainy Street 11562, Cairo, Egypt. diana.aziz@pharma.cu.edu.eg.
Zitieren
APA
El Halawany, M., Sharaky, M., & Aziz, D. (2025). Stearyl amine tailored spanlastics embedded within tetronic® nanogel for boosting the repurposed anticancer potential of mebendazole: formulation, in vitro profiling, cytotoxicity assessment, and in vivo permeation analysis. DARU Journal of Pharmaceutical Sciences. https://doi.org/10.1007/s40199-025-00560-3
Vancouver
El Halawany M, Sharaky M, Aziz D. Stearyl amine tailored spanlastics embedded within tetronic® nanogel for boosting the repurposed anticancer potential of mebendazole: formulation, in vitro profiling, cytotoxicity assessment, and in vivo permeation analysis. DARU Journal of Pharmaceutical Sciences. 2025. doi:10.1007/s40199-025-00560-3
BibTeX
@article{ElHalawany2025,
author = {El Halawany, Mai and Sharaky, Marwa and Aziz, Diana},
title = {Stearyl amine tailored spanlastics embedded within tetronic® nanogel for boosting the repurposed anticancer potential of mebendazole: formulation, in vitro profiling, cytotoxicity assessment, and in vivo permeation analysis},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2025},
doi = {10.1007/s40199-025-00560-3}
}
EUVIMED